Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Nivolumab and relatlimab-rmbw |
| Synonyms | |
| Therapy Description |
Opdualag (nivolumab and relatlimab-rmbw) is a fixed-dose combination of Relatlimab (BMS-986016) and Opdivo (nivolumab), which may lead to enhanced anti-tumor immune response (PMID: 34986285). Opdualag (nivolumab and relatlimab-rmbw) is FDA approved for use in adult and pediatric patients of 12 years or older with unresectable or metastatic melanoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Nivolumab and relatlimab-rmbw | Opdualag | BMS-986213 | LAG3 Antibody 18 PD-L1/PD-1 antibody 105 | Opdualag (nivolumab and relatlimab-rmbw) is a fixed-dose combination of Relatlimab (BMS-986016) and Opdivo (nivolumab), which may lead to enhanced anti-tumor immune response (PMID: 34986285). Opdualag (nivolumab and relatlimab-rmbw) is FDA approved for use in adult and pediatric patients of 12 years or older with unresectable or metastatic melanoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05418972 | Phase II | Nivolumab and relatlimab-rmbw | A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (Neo ReNi II) | Not yet recruiting | 1 | |
| NCT05328908 | Phase III | Regorafenib + Trifluridine-tipiracil hydrochloride Nivolumab and relatlimab-rmbw | A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 14 |
| NCT05704647 | Phase II | Nivolumab and relatlimab-rmbw | Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases | Recruiting | USA | 0 |
CKB BOOST